ARWR
Income statement / Annual
Last year (2025), Arrowhead Pharmaceuticals, Inc.'s total revenue was $829.45 M,
an increase of 23,258.15% from the previous year.
In 2025, Arrowhead Pharmaceuticals, Inc.'s net income was -$1.63 M.
See Arrowhead Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
09/30/2025 |
09/30/2024 |
09/30/2023 |
09/30/2022 |
09/30/2021 |
09/30/2020 |
09/30/2019 |
09/30/2018 |
09/30/2017 |
09/30/2016 |
| Operating Revenue |
$829.45 M |
$3.55 M |
$240.74 M |
$243.23 M |
$138.29 M |
$87.99 M |
$168.80 M |
$16.14 M |
$31.41 M |
$158.33 K |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$3.55 M
|
$240.74 M
|
$243.23 M
|
$138.29 M
|
$87.99 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$607.16 M
|
$505.87 M
|
$353.19 M
|
$297.31 M
|
$206.34 M
|
$128.88 M
|
$81.05 M
|
$52.97 M
|
$50.90 M
|
$62.12 M
|
| General & Administrative Expenses |
$123.94 M
|
$96.82 M
|
$90.93 M
|
$124.43 M
|
$80.98 M
|
$52.28 M
|
$26.56 M
|
$19.11 M
|
$17.50 M
|
$23.59 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$123.94 M
|
$96.82 M
|
$90.93 M
|
$124.43 M
|
$80.98 M
|
$52.28 M
|
$26.56 M
|
$19.11 M
|
$17.50 M
|
$23.59 M
|
| Other Expenses |
$0.00
|
$1.94 M
|
$1.62 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$5.86 M
|
| Operating Expenses |
$731.10 M
|
$604.63 M
|
$445.74 M
|
$421.74 M
|
$287.32 M
|
$181.15 M
|
$107.61 M
|
$72.08 M
|
$68.40 M
|
$79.85 M
|
| Cost And Expenses |
$0.00
|
$604.63 M
|
$445.74 M
|
$421.74 M
|
$287.32 M
|
$181.15 M
|
$107.61 M
|
$72.08 M
|
$68.40 M
|
$79.85 M
|
| Interest Income |
$37.29 M
|
$22.72 M
|
$15.30 M
|
$5.03 M
|
$6.12 M
|
$9.19 M
|
$6.96 M
|
$1.05 M
|
$415.13 K
|
$265.79 K
|
| Interest Expense |
$89.36 M
|
$32.35 M
|
$18.33 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$18.60 M
|
$12.49 M
|
$10.42 M
|
$8.27 M
|
$5.94 M
|
$4.44 M
|
$4.70 M
|
$4.69 M
|
$3.26 M
|
| EBITDA |
$98.35 M |
-$561.51 M |
-$175.67 M |
-$162.29 M |
-$132.58 M |
-$87.22 M |
$65.63 M |
-$51.24 M |
-$32.31 M |
-$76.43 M |
| EBITDA Ratio |
0.12
|
-158.13
|
-0.73
|
-0.67
|
-0.96
|
-0.99
|
0.39
|
-3.17
|
-1.03
|
-482.73
|
| Operating Income Ratio |
0.12
|
-169.27
|
-0.85
|
-0.73
|
-1.08
|
-1.06
|
0.36
|
-3.47
|
-1.18
|
-516.27
|
| Total Other Income/Expenses Net |
$0.00
|
-$11.38 M
|
-$1.49 M
|
$5.80 M
|
$8.19 M
|
$8.61 M
|
$6.96 M
|
$1.49 M
|
$2.62 M
|
$22.12 K
|
| Income Before Tax |
$19.79 M
|
-$612.46 M
|
-$206.49 M
|
-$172.71 M
|
-$140.85 M
|
-$84.55 M
|
$68.15 M
|
-$54.45 M
|
-$34.38 M
|
-$81.72 M
|
| Income Before Tax Ratio |
0.02
|
-172.48
|
-0.86
|
-0.71
|
-1.02
|
-0.96
|
0.4
|
-3.37
|
-1.09
|
-516.13
|
| Income Tax Expense |
$21.42 M
|
-$2.77 M
|
$2.78 M
|
$3.79 M
|
$2.00 K
|
$2.00 K
|
$174.00 K
|
$2.40 K
|
$2.40 K
|
$2.40 K
|
| Net Income |
-$1.63 M
|
-$599.49 M
|
-$205.28 M
|
-$176.06 M
|
-$140.85 M
|
-$84.55 M
|
$67.98 M
|
-$54.45 M
|
-$34.38 M
|
-$81.72 M
|
| Net Income Ratio |
-0
|
-168.82
|
-0.85
|
-0.72
|
-1.02
|
-0.96
|
0.4
|
-3.37
|
-1.09
|
-516.15
|
| EPS |
-0.01 |
-5 |
-1.91 |
-1.67 |
-1.36 |
-0.84 |
0.72 |
-0.65 |
-0.47 |
-1.34 |
| EPS Diluted |
-0.01 |
-5 |
-1.92 |
-1.67 |
-1.36 |
-0.84 |
0.69 |
-0.65 |
-0.47 |
-1.34 |
| Weighted Average Shares Out |
$133.76 M
|
$119.78 M
|
$107.31 M
|
$105.43 M
|
$103.75 M
|
$100.72 M
|
$93.86 M
|
$83.64 M
|
$73.15 M
|
$60.99 M
|
| Weighted Average Shares Out Diluted |
$133.76 M
|
$119.78 M
|
$106.75 M
|
$105.43 M
|
$103.75 M
|
$100.72 M
|
$98.61 M
|
$83.64 M
|
$73.90 M
|
$61.05 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
